Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Soraprazan in Stargardt disease
NL-OMON48130Phase 2Recruiting
- Sponsor
- Katairo
- Start
- Jun 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Fundus Flavimaculatus (FF) comparing Soraprazan with Placebo (2 arms). Primary endpoint: Change in qAF8 score from baseline to end of treatment. Started Jun 2019; status: recruiting.
02
Drugs
soraprazan
03
Conditions
Fundus Flavimaculatus (FF)
Beyond the preview
Go deeper on NL-OMON48130.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON48130.